Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (VNRX) is pioneering epigenetic diagnostics through its nucleosomics platform, developing non-invasive blood tests for early cancer detection and NETosis-related conditions. This resource provides investors and healthcare professionals with comprehensive access to verified company developments and clinical milestones.
Our curated news collection delivers timely updates on regulatory progress, partnership announcements, and research breakthroughs. Users will find essential information spanning clinical trial results, licensing agreements, veterinary diagnostic expansions, and financial performance reports.
The page features critical updates including technology validations, international market entries, and peer-reviewed study publications. All content is rigorously verified to ensure accuracy and relevance for strategic decision-making.
Bookmark this page for structured access to VolitionRx's evolving diagnostic solutions across human and animal health sectors. Check regularly for authoritative reporting on innovations transforming routine disease detection through advanced epigenetic analysis.
VolitionRx Limited (NYSE American: VNRX) has announced the pre-order availability of its Nu.Q® Vet Cancer Test for veterinarians through Heska Corporation (NASDAQ: HSKA). This innovative test will be showcased at the 2023 Western Veterinary Conference in Las Vegas. The Nu.Q® test operates on Heska's Element i+® Immunodiagnostic Analyzer, providing rapid and accurate on-site testing for under $50, assisting in early cancer detection in dogs. The collaboration signifies a breakthrough in making Volition's Nucleosomics™ technology accessible at the point of care, enhancing veterinary care and patient outcomes. The commercial launch is targeted for early Q2 2023.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced participation in a webinar on January 26, 2023, focusing on the Nu.Q® Vet commercial strategy. Key speakers include CEO Dr. Tom Butera and Chief Medical Officer Dr. Heather Wilson Robles. The event aims to provide insights into the Nu.Q® Vet Cancer Test, a cost-effective blood test for early detection in dogs. Volition is exploring significant market opportunities in companion animal healthcare. The webinar will be recorded for later access. Volition develops blood tests for diagnosing diseases, leveraging its Nucleosomics™ platform.
VolitionRx Limited (NYSE AMERICAN: VNRX) has announced the launch of its Nu.Q® Vet Cancer Test through the IDEXX Laboratories reference laboratory network in the U.S. This innovative blood test is designed to detect cancer in older or at-risk dogs, leveraging Volition's Nucleosomics™ technology. IDEXX aims to use this test to enhance pet health and wellbeing by facilitating earlier diagnosis and treatment. With a significant potential market, this partnership is expected to expand Volition’s reach in the companion animal healthcare sector.
VolitionRx Limited (NYSE AMERICAN: VNRX) released its 2022 Business Review, highlighting significant progress as it transitions from an R&D-focused entity to one with commercial operations. Key achievements include global expansion of the Nu.Q® Vet Cancer Test, obtaining a CE mark for Nu.Q® NETs, initiating U.S. clinical product programs, and scaling operations. President Cameron Reynolds emphasized the company's advancements in epigenetics and its commitment to improving health outcomes.
VolitionRx Limited (NYSE AMERICAN: VNRX) reported its third-quarter financial results for the period ending September 30, 2022. The company held a conference call on November 15, 2022, to discuss these results. Volition's cash and cash equivalents totaled approximately $16.4 million. The company received $6.4 million from a public offering and $1.5 million from non-dilutive funding. The Nu.Q® Vet Cancer Test launched in the U.S. and will soon be available in Europe. Volition aims to license its Nu.Q® platform and continues advancing several key clinical studies.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced a clinical study in collaboration with Oncovet to evaluate its Nu.Q® Vet Cancer Test in dogs and cats with cancer. Led by Dr. Jérôme Benoit, the study aims to assess the detection of various systemic cancers by measuring circulating nucleosomes. The research will involve samples from 100 dogs and 25 cats and is expected to enhance the test's applications in Europe. Previous studies indicated the Nu.Q® Vet Cancer Test detected 76% of systemic cancers with 97% specificity.
VolitionRx Limited (NYSE AMERICAN: VNRX) has been invited to join a government-backed study in France to assess blood biomarkers for early lung cancer detection, partnering with Hospices Civils de Lyon. The ILYAD study aims to evaluate Volition's Nu.Q® test in detecting lung cancer, involving over 400 subjects over the next year. Chief Commercial Officer Gael Forterre emphasized the critical need for effective lung cancer screening globally. Volition specializes in developing cost-effective blood tests using its innovative Nucleosomics™ technology.
VolitionRx Limited (NYSE AMERICAN: VNRX) has launched its Nu.Q® Vet Cancer Screening Test across the U.S. and plans to expand into Europe via Heska Corporation (NASDAQ: HSKA). The test offers an accurate, affordable, and non-invasive method for early cancer detection in dogs. With approximately 84 million pet dogs in the U.S., this screening can enhance health outcomes by facilitating early treatment. This partnership aligns with Heska's growth strategy in advanced veterinary diagnostics, following a $28 million licensing agreement with Volition.
VolitionRx Limited (NYSE AMERICAN: VNRX) has signed a global supply agreement with a leading pet healthcare provider to supply the Nu.Q® Vet Cancer Test via its laboratory network. This test aims at early cancer detection in pets, particularly senior dogs, providing significant market potential given the 84 million pet dogs in the U.S. Dr. Tom Butera emphasized that this agreement helps commercialize their technology in animal healthcare. Clinical studies indicate the test can detect 76% of systemic cancers with high specificity.
Xenetic Biosciences (NASDAQ: XBIO) announced the signing of a patent assignment from CLS Therapeutics as part of a collaboration with CLS and VolitionRx (NYSE AMERICAN: VNRX) to develop NETs-targeted adoptive cell therapies for cancer. In exchange for the patent, Xenetic will issue 850,000 shares to CLS. This collaboration aims to combine Volition's Nu.Q technology and Xenetic's DNase-Armored CAR T platform, targeting various solid tumors where current therapies are ineffective. The partnership will also share proceeds from any resulting commercial products.